Health

Forty Seven

Acquired - Gilead

With a passion to help patients defeat their cancer, Forty Seven is committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity. On March 2nd, 2020, Gilead announced it will acquire Forty Seven for $4.9 billion.

fortyseveninc.com

U.S.

Therapeutics

Leaders
Mark McCamish, M.D., Ph.D.

CEO & Board member

Ravindra Majeti, M.D., Ph.D.

founder & board member

Mark Chao, M.D., Ph.D.

Founder & SVP, Head of Clinical Development

Jens-Peter Volkmer, M.D.

Founder & VP of R&D

Prof Irv Weissman

Founder & Board Member

With a passion to help patients defeat their cancer, Forty Seven is committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity. On March 2nd, 2020, Gilead announced it will acquire Forty Seven for $4.9 billion.